A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 6, 2013, Pages 495-504

  Maison Blanche, Pierre ^a   Vermorken, Jan B ^b   Goksel, Tuncay ^c   Machiels, Jean Pascal ^d   Agarwala, Sanjiv ^e   Rottey, Sylvie ^f   Daugaard, Gedske ^g   Volovat, Constantin ^h   Scheulen, Max ⁱ   Sengeløv, Lisa ^j   Grecea, Dana ^k   Eniu, Alexandru ^k   Jäger, Elke ^l   Meiri, Eyal ^m   Cascinu, Stefano ⁿ   Strumberg, Dirk ^o   Demir, Gokhan ^p   Clemens, Michael ^q   Pinotti, Graziella ^r   Nardi, Mario ^s   Guthrie, Troy ^t   Boelle, Emmanuelle ^u   Magherini, Emmanuelle ^u   more..

^a BICHAT HOSPITAL   (France)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c EGE UNIVERSITY   (Turkey)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e ST LUKE S HOSPITAL   (United States)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^h Center of Medical Oncology Iasi   (Romania)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^l KRANKENHAUS NORDWEST   (Germany)

^m Palm Beach Institute of Hematology and Oncology   (United States)

ⁿ OSPEDALI RIUNITI   (Italy)

^o RUHR UNIVERSITY BOCHUM   (Germany)

^p ISTANBUL BILIM UNIVERSITY   (Turkey)

^q Klinik fur Innere Medizin i   (Germany)

^r OSPEDALE DI CIRCOLO   (Italy)

^s BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^t Baptist Regional Cancer Institute   (United States)

^u SANOFI   (France)

more..

Author keywords

Aflibercept; Anti VEGF; Cardiac safety; QTc; Solid tumors

Indexed keywords

AFLIBERCEPT; DOCETAXEL; PLACEBO;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HEART REPOLARIZATION; HUMAN; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TAXOIDS; VENTRICULAR FUNCTION;

EID: 84879881931     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31828b73ff     Document Type: Article

References (20)

1. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res. 2007;13:s4623-s4627.
2. Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf. 2010;5: 93-96.
3. Riess H, Manges R, Karasek P, et al. Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: final results. Ann Oncol. 2010;21. Abstract O-0006.
4. Novello S, Ramlau R, Gorbunova VA, et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). J Thorac Oncol. 2011;6:2S. Abstract 511.
5. Tabernero J, Van Cutsem E, Lakomy R, et al. Results from VELOUR, a phase 3 study of aflibercept (A) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients (pt) with previously treated metastatic colorectal cancer (MCRC). Eur J Cancer. 2011;47(suppl 2). Abstract.
6. Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (Folfiri) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-Velour). Ann Oncol. 2011;22(suppl 5). Abstract O-0024.
7. International Conference on Harmonisation. S7B The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH/423/02. 2005.
8. International Conference on Harmonisation. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2005.
9. Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7: 305-318.
10. Boehm S, Rothermundt C, Hess D, et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology. 2010;56: 303-309.
11. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25: 4278-4284.
12. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16: 1391-1397.
13. Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15: 7045-7052.
14. Isambert N, Freyer GJ, Zanetta S, et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2012;15: 1743-1750.
15. Arizona Center for Education and Research on Therapeutics. QT Drug List by risk group. Available at: http://arizonacert.org/medical-pros/druglists/ bycategory.cfm. Accessed June 2008.
16. Food and Drug Administration. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/nda/2011/022405Orig1s000PharmR.pdf. Accessed March 25, 2011.
17. Dennis AT, Wang L, Wan H, et al. Molecular determinants of pentamidine- induced hERG trafficking inhibition. Mol Pharmacol. 2012;81: 198-209.
18. Obers S, Staudacher I, Ficker E, et al. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol. 2010;381: 385-400.
19. Rodriguez I, Erdman A, Padhi D, et al. Electrocardiographic assessment for therapeutic proteins - scientific discussion. Am Heart J. 2010;160: 627-634.
20. Morganroth J, Shah RR, Scott JW. Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). Clin Pharmacol Ther. 2010;87: 166-174.